Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

被引：0
|
作者：
Vrdoljak, E.
Marschner, N.
Zielinski, C.
Gligorov, J.
Cortes, J.
Puglisi, F.
Aapro, M.
Fallowfield, L.
Fontana, A.
Inbar, M.
Kahan, Z.
Welt, A.
Levy, C.
Brain, E.
Pivot, X.
Putzu, C.
Gonzalez-Martin, A.
Ebel, K.
Easton, V.
von Minckwitz, G.
机构：
[1] Ctr Oncol, Split, Croatia
[2] Outpatient Canc Ctr, Freiburg, Germany
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] CECOG, Vienna, Austria
[5] Hop Tenon, F-75970 Paris, France
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Univ Hosp Udine, Udine, Italy
[8] Clin Genolier, Inst Multidisciplinaire Oncol, Genolier, Switzerland
[9] Univ Sussex, Brighton & Sussex Med Sch, SHORE C, Falmer, England
[10] Univ Hosp Pisa, Ist Toscana Tumori, Pisa, Italy
[11] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[12] Univ Szeged, Szeged, Hungary
[13] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[14] Ctr Francois Baclesse, F-14021 Caen, France
[15] Hop Rene Huguenin, Inst Curie, St Cloud, France
[16] Univ Hosp Jean Minjoz, Besancon, France
[17] Univ Hosp Sassari, Sassari, Italy
[18] MD Anderson Canc Ctr, Madrid, Spain
[19] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[20] Stamford Consultants AG, Basel, Switzerland
[21] German Breast Grp, Neu Isenburg, Germany
[22] Univ Womens Hosp, Frankfurt, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P6-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [2] TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).
    von Minckwitz, G.
    Cortes, J.
    Gligorov, J.
    Marschner, N. W.
    Puglisi, F.
    Vrdoljak, E.
    Duenne, A-A
    Zielinski, C.
    CANCER RESEARCH, 2011, 71
  • [3] Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)
    Cortes, Javier
    Vrdoljak, Eduard
    Puglisi, Fabio
    Marschner, Norbert
    Gligorov, Joseph
    Zielinski, Christoph
    Villanueva, Cristian
    Romieu, Gilles
    Lang, Istvan
    Ciruelos, Eva
    Veyret, Corinne
    Fontana, Andrea
    Oestergaard, Mikkel
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [4] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [5] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C.
    Gligorov, J.
    Marschner, N.
    Puglisi, F.
    Vrdoljak, E.
    Castan, J. Cortes
    de Ducla, S.
    Deurloo, R.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [7] BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL
    Gligorov, J.
    Alba-Conejo, E.
    Bines, J.
    Cortes, P. A.
    Doval, D. C.
    Jiang, Z.
    Freudensprung, U.
    Mustacchi, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 128 - 128
  • [8] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [9] Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
    Gligorov, Joseph
    Bines, Jose
    Alba, Emilio
    Mustacchi, Giorgio
    Cinieri, Saverio
    Gupta, Vineet
    Pierga, Jean-Yves
    Bozcuk, Hakan
    Gaafar, Rabab
    Gupta, Sudeep
    Vivanco, Guillermo Lopez
    Wang, Xiaojia
    Costa, Romulo
    Altundag, Kadri
    Chmielowska, Ewa
    de Ducla, Sabine
    Freudensprung, Ulrich
    Cortes, Paulo
    Doval, Dinesh
    CANCER RESEARCH, 2015, 75
  • [10] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
12345